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
| Management number | 253536122 | Release Date | 2026/10/24 | List Price | CA$36.00 | Model Number | 253536122 | ||
|---|---|---|---|---|---|---|---|---|---|
| Category | |||||||||
Genesis Story August 2024
Lee Charles Research was formed in 2024 by Private Label Distillery Owner, Paul Thomas Dunning.
Lee is Paul’s mother’s middle name & Charles his father’s middle name. Lee Charles Research mission is to end stage 2 cancers by 2045 through promising DNA fragment cancer testing.
At 44, Paul is fighting stage 4 colon cancer that developed in his mid 30s and he has decided to spend 50% of his remaining time developing cancer prevention, treatment and research (C-PTR).
Lee Charles will start offering Global AI Assisted Clinical Trial Monitoring (GAACTM) by December 31st 2024.
Roughly 18% of patients die from cancer when clinical trials are available simply because the patient does not know about the trial.
100% of profits donated to Lee Charles Research
If you notice any omissions or errors in the product information on this page, please use the correction request form below.
Correction Request Form